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
| Management number | 253536122 | Release Date | 2026/10/24 | List Price | CA$36.00 | Model Number | 253536122 | ||
|---|---|---|---|---|---|---|---|---|---|
| Category | |||||||||
Genesis Story August 2024
Lee Charles Research was formed in 2024 by Private Label Distillery Owner, Paul Thomas Dunning.
Lee is Paul’s mother’s middle name & Charles his father’s middle name. Lee Charles Research mission is to end stage 2 cancers by 2045 through promising DNA fragment cancer testing.
At 44, Paul is fighting stage 4 colon cancer that developed in his mid 30s and he has decided to spend 50% of his remaining time developing cancer prevention, treatment and research (C-PTR).
Lee Charles will start offering Global AI Assisted Clinical Trial Monitoring (GAACTM) by December 31st 2024.
Roughly 18% of patients die from cancer when clinical trials are available simply because the patient does not know about the trial.
100% of profits donated to Lee Charles Research
If you notice any omissions or errors in the product information on this page, please use the correction request form below.
Correction Request Form